Isopropyl-thiazol-2-ylmethyl-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Isopropyl-thiazol-2-ylmethyl-amine
• 英文别名: N-(1,3-thiazol-2-ylmethyl)propan-2-amine
• 化学式: C₇H₁₂N₂S
• 分子量: 156.25
• InChiKey: NMLFQGGSZUWMQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Carbamate compounds
  申请人：Fu Hong

  公开号：US20080214617A1

  公开（公告）日：2008-09-04

  Carbamate compounds having a structure represented by formula I (where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein) are useful as anti-tumor agents.

  具有由公式I表示的结构的氨基甲酸酯化合物（其中R1，R2，R3，R4，R5和R6如本文所定义）可用作抗肿瘤剂。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• AMIDE COMPOUNDS AND THE USE THEREOF
  申请人：Matsumura Akira

  公开号：US20110190300A1

  公开（公告）日：2011-08-04

  The invention relates to amide compounds of Formula I: (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, etc.; R 1 and R 2 are each independently hydrogen, halogen, cyano, optionally substituted lower alky, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl etc. R 3 and R 4 are hydrogen, each optionally substituted lower alkyl, cycloalkyl, aryl or heterocyclyl etc.; X is ═O, optionally substituted lower alkyl, halogen, cyano, nitro etc., n is 0-5, m is 1 or 2 and p is 0-2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及公式I的酰胺化合物：（I）及其药学上可接受的盐，前药和溶剂化物，其中：Y为CO或SOm；Z为每个可选取代的较低烷基，较低烯基，环烷基，芳基，杂环烷基等；R1和R2分别独立地为氢，卤素，氰基，可选取代的较低烷基，可选取代的环烷基，可选取代的芳基或可选取代的杂环烷基等。R3和R4为氢，每个可选取代的较低烷基，环烷基，芳基或杂环烷基等；X为═O，可选取代的较低烷基，卤素，氰基，硝基等，n为0-5，m为1或2，p为0-2。本发明还涉及使用公式I的化合物治疗、预防或改善对钙通道阻滞剂有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• NOVEL BICYCLIC BROMODOMAIN INHIBITORS
  申请人：ZENITH EPIGENETICS CORP.

  公开号：US20160159801A1

  公开（公告）日：2016-06-09

  The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

  该发明涉及用于通过结合溴域抑制BET蛋白功能的取代双环化合物，包括这些化合物的制药组合物以及在治疗中使用这些化合物和组合物。
• Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP2042173A2

  公开（公告）日：2009-04-01

  The present invention provides κ opioid receptor agonists comprising 2-phenylbenzothiazoline derivatives. The present invention relates to κ opioid receptor agonists comprising compounds or salts thereof having the chemical structure represented by the general formula [I]. Namely, it is important for exhibition of the κ opioid receptor agonist actions to have an alkyl group having an amino group at a phenyl group of 2-phenylbenzothiazoline as a substituent and to have an acyl group at a nitrogen atom of 2-phenylbenzothiazoline, wherein R is alkyl having the amino group as the substituent; and R1 is acyl.

  本发明提供了由 2-苯基苯并噻唑啉衍生物组成的 κ 阿片受体激动剂。本发明涉及由具有通式[I]所代表的化学结构的化合物或其盐组成的κ阿片受体激动剂。也就是说，对于展示κ阿片受体激动剂的作用来说，重要的是在2-苯基苯并噻唑啉的苯基上具有氨基的烷基作为取代基，并且在2-苯基苯并噻唑啉的氮原子上具有酰基、 其中 R 是以氨基为取代基的烷基；R1 是酰基。